Comparison
3 Methylglutaconic Aciduria Type Viib C5676893 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 3 Methylglutaconic Aciduria Type Viib and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type Viib C5676893
A rare genetic metabolic condition impacting mitochondria, similar to type VIIa. It causes neurological and developmental problems that require lifelong management. Treatment involves supportive therapies tailored to individual symptoms.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type Viib C5676893
0-5
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type Viib C5676893
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type Viib C5676893
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type Viib C5676893
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type Viib C5676893
metabolic
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type Viib C5676893
metabolic
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-viib-C5676893 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type Viib C5676893 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Developmental delay | Early neurological and developmental problems linked to mitochondrial dysfunction. | Developmental delay and intellectual disability associated with missing 3q13 material. | Low |
| Metabolic clues | May include abnormal organic-acid findings, especially 3-methylglutaconic acid. | No characteristic organic-acid abnormality is established by the supplied description. | High |
| Congenital features | Primarily a metabolic-neurologic condition; specific congenital pattern is not established. | May include variable congenital features alongside developmental problems. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type Viib C5676893 when
Early-onset severe neurologic or developmental illness
Fits the described childhood onset and severe metabolic course better than a variable congenital syndrome.
Moderate
Suspected mitochondrial metabolic disorder
The condition is described as mitochondrial and similar to type VIIa.
High
Abnormal organic-acid testing
An elevated 3-methylglutaconic acid result supports targeted metabolic evaluation, but is not itself a diagnosis.
Moderate
Choose 3q13 Microdeletion Syndrome C2931338 when
Chromosomal microarray shows a 3q13 deletion
A confirmed relevant deletion directly supports this syndrome, pending clinical correlation.
High
Developmental delay with congenital anomalies
This pattern aligns with the described chromosomal disorder more than a primary metabolic aciduria.
Moderate
Variable age at recognition without metabolic markers
The supplied onset is variable and no characteristic metabolic abnormality is described.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type Viib C5676893 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show 3-methylglutaconic acid elevation; no cutoff is supplied. | No characteristic abnormality is established. | An abnormal result suggests metabolic evaluation but does not alone confirm type VIIb. |
| Chromosomal microarray | Not expected to identify the primary metabolic diagnosis. | May detect missing material at 3q13. | Deletion size, genes involved, and phenotype require specialist interpretation. |
| Genetic or mitochondrial evaluation | Targeted genetic testing may be considered after metabolic findings. | Cytogenomic testing is the central diagnostic approach. | Test choice should follow clinical genetics guidance; a specific causative result is not supplied here. |
Prognosis comparison
3 Methylglutaconic Aciduria Type Viib C5676893
- Outcome
- Potentially severe chronic neurologic and developmental course; precise outcomes are not established.
- Factors
- Age at onset, neurologic findings, metabolic stability, and supportive-care needs.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Generally described as moderate but variable; individual outcomes are not established.
- Factors
- Deletion characteristics, congenital findings, developmental level, and available therapies.
Time frame: Lifelong, with childhood recognition common but timing variable.
Prognosis should be individualized; no reliable mortality or universal milestone data are supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Described as a major feature and may be severe. Developmental and intellectual impairment may occur with variable severity. Neither condition has a universally fixed neurologic course in the supplied data. |
| Developmental disability | Lifelong developmental support may be needed. Intellectual disability and developmental delay are characteristic concerns. Educational and therapy needs should be individualized. |
| Multisystem involvement | Mitochondrial disease can affect multiple systems, but exact complications are not established here. Congenital features may involve multiple systems, with variable expression. Surveillance should be guided by each patient's findings rather than a fixed list. |
Patient education highlights
- HighDiagnosis versus test result
An abnormal laboratory or genetic finding needs confirmation and clinical correlation before it is treated as a diagnosis.
- HighLifelong care
Both conditions are chronic; care is supportive and tailored because no definitive disease-modifying regimen is established here.
- MediumFamily implications
Genetic counseling can explain inheritance, testing of relatives, and reproductive options without assuming a specific result.